Oral small molecule GLP-1 receptor agonist
Danuglipron 140 mg tablet twice daily
DANU_PO_140MG_BID
Related
- All doses pooled: Danuglipron tablet
- Danuglipron 200 mg oral twice daily
- Danuglipron 80 mg oral twice daily
- Danuglipron 40 mg oral twice daily
- Danuglipron 120 mg oral twice daily
- Danuglipron 160 mg oral twice daily
- Danuglipron 2.5 mg tablet twice daily
- Danuglipron 10 mg tablet twice daily
- Danuglipron 3 mg tablet
- Danuglipron 10 mg tablet
- Danuglipron 30 mg tablet
- Danuglipron 100 mg tablet
- Danuglipron 300 mg tablet
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.10 (0.20 to 24.74) | 0.37 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 10.38 (2.34 to 69.66) | 0.13 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.78 (2.96 to 32.22) | 0.17 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.79 (1.46 to 33.80) | 0.39 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.95 (0.71 to 16.96) | 0.34 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.49 (0.07 to 3.22) | 0.83 |